Laurent Pharmaceuticals extends COVID-19 Phase 2 study with oral antiviral LAU-7b that has showed 100% reduction in the risk of progression onto mechanical ventilation and death

FDA allows Phase 2 study extension focusing on moderate-to-severe COVID-19 patients and grants Type B meeting to discuss eligibility to Emergency Use Authorization (EUA) and Phase 3 clinical developmentLAU-7b is…

Continue ReadingLaurent Pharmaceuticals extends COVID-19 Phase 2 study with oral antiviral LAU-7b that has showed 100% reduction in the risk of progression onto mechanical ventilation and death

Laurent Pharmaceuticals Announces Topline Results from its Phase 2 RESOLUTION Clinical Trial of LAU-7b for the Treatment of COVID-19

Laurent Pharmaceuticals Inc., a clinical-stage biopharmaceutical company developing LAU-7b, a first-in-class pro-resolving drug candidate, reported today topline results from its Phase 2 RESOLUTION clinical trial in hospitalized COVID-19 patients. This…

Continue ReadingLaurent Pharmaceuticals Announces Topline Results from its Phase 2 RESOLUTION Clinical Trial of LAU-7b for the Treatment of COVID-19

Laurent Pharmaceuticals Completes Patients Enrollment in Phase 2 Study of LAU-7b for the Treatment of COVID-19

Laurent Pharmaceuticals Inc., a clinical-stage biopharmaceutical company developing the first-in-class pro-resolving drug LAU-7b, today announces that it has completed the enrollment for its placebo-controlled Phase 2 RESOLUTION clinical study of…

Continue ReadingLaurent Pharmaceuticals Completes Patients Enrollment in Phase 2 Study of LAU-7b for the Treatment of COVID-19